Wachter, Rolf

[["dc.bibliographiccitation.firstpage","59"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","74"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Schwarz, Silja"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Mensching, Steffen"],["dc.contributor.author","Siegmund, Friederike"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Düngen, Hans-Dirk"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2019-07-09T11:41:03Z"],["dc.date.available","2019-07-09T11:41:03Z"],["dc.date.issued","2014"],["dc.description.abstract","Background The long-term effects of exercise training (ET) in diastolic dysfunction (DD) and heart failure with preserved ejection fraction (HFpEF) are unknown. The present study compared the long-term effects of ET on exercise capacity, diastolic function, and quality of life (QoL) in patients with DD vs. HFpEF. Methods A total of n=43 patients with asymptomatic DD (n=19) or HFpEF [DD and New York Heart Association (NYHA) ≥II, n=24] and left ventricular ejection fraction ≥50% performed a combined endurance/resistance training over 6months (2–3/week) on top of usual care. Cardiopulmonary exercise testing, echocardiography, and QoL were obtained at baseline and follow-up. Results Patients were 62±8 years old (37% female). In the HFpEF group, 67% of patients were in NYHA class II (33% in NYHA III). Exercise capacity (peak oxygen consumption, peak VO2) differed at baseline (DD 29.2±8.7mL/min/kg vs. HFpEF 17.8±4.6 mL/min/kg; P=0.004). After 6months, peak VO2 increased significantly (P<0.044) to 19.7±5.8 mL/min/kg in the HFpEF group and also in the DD group (to 32.8±8.5mL/min/kg; P<0.002) with no overall difference between the groups (P=0.217). E/e′ ratio (left ventricular filling index) decreased from 12.2±3.5 to 10.1±3.0 (P<0.002) in patients with HFpEFand also in patients with DD (10.7±3.1 vs. 9.5±2.3; P=0.03; difference between groups P=0.210). In contrast, left atrial volume index decreased in the HFpEF group (P<0.001) but remained stable within the DD group (difference between groups P=0.015). After 6 months, physical QoL (Minnesota living with heart failure Questionnaire, 36-item short form health survey), general health perception, and 9-item patient health questionnaire score only improved in HFpEF (P<0.05). In contrast, vitality improved in both groups (difference between groups P=0.708). Conclusion A structured 6 months ET programme effectively improves exercise capacity and diastolic function in patients with DD and overt HFpEF. Therefore, controlled lifestylemodification with physical activity is effective both in DD and HFpEF."],["dc.identifier.doi","10.1002/ehf2.12007"],["dc.identifier.fs","610857"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11651"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58349"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1879-0844"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Effects of long-term endurance and resistance training on diastolic function, exercise capacity, and quality of life in asymptomatic diastolic dysfunction vs. heart failure with preserved ejection fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2296"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Biomedicines"],["dc.bibliographiccitation.volume","10"],["dc.contributor.affiliation","Lechner, Katharina; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","von Schacky, Clemens; 4Omegametrix, Martinsried, 82152 Munich, Germany"],["dc.contributor.affiliation","Scherr, Johannes; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Lorenz, Elke; 3Kardiologie, Deutsches Herzzentrum München, 80636 Munich, Germany"],["dc.contributor.affiliation","Bock, Matthias; 2DZHK (German Centre for Cardiovascular Research), Partner Site Munich, Munich Heart Alliance, 80336 Munich, Germany"],["dc.contributor.affiliation","Lechner, Benjamin; 6Department of Internal Medicine IV, Ludwig-Maximilians University, 80336 Munich, Germany"],["dc.contributor.affiliation","Haller, Bernhard; 7Institute of AI and Informatics in Medicine, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany"],["dc.contributor.affiliation","Krannich, Alexander; 8Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany"],["dc.contributor.affiliation","Halle, Martin; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Wachter, Rolf; 9Clinic and Policlinic for Cardiology, University Hospital Leipzig, 04103 Leipzig, Germany"],["dc.contributor.affiliation","Duvinage, André; 1Rehabilitation and Sports Medicine, Department of Prevention, School of Medicine, Technical University of Munich, 80992 Munich, Germany"],["dc.contributor.affiliation","Edelmann, Frank; 12Department of Cardiology, Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany"],["dc.contributor.author","Lechner, Katharina"],["dc.contributor.author","von Schacky, Clemens"],["dc.contributor.author","Scherr, Johannes"],["dc.contributor.author","Lorenz, Elke"],["dc.contributor.author","Bock, Matthias"],["dc.contributor.author","Lechner, Benjamin"],["dc.contributor.author","Haller, Bernhard"],["dc.contributor.author","Krannich, Alexander"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Duvinage, André"],["dc.contributor.editor","Drozd, Arleta"],["dc.date.accessioned","2022-10-04T10:21:47Z"],["dc.date.available","2022-10-04T10:21:47Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:13:12Z"],["dc.description.abstract","Background: Circulating long-chain (LCSFAs) and very long-chain saturated fatty acids (VLSFAs) have been differentially linked to risk of incident heart failure (HF). In patients with heart failure with preserved ejection fraction (HFpEF), associations of blood SFA levels with patient characteristics are unknown. Methods: From the Aldo-DHF-RCT, whole blood SFAs were analyzed at baseline in n = 404 using the HS-Omega-3-Index® methodology. Patient characteristics were 67 ± 8 years, 53% female, NYHA II/III (87%/13%), ejection fraction ≥50%, E/e’ 7.1 ± 1.5; and median NT-proBNP 158 ng/L (IQR 82–298). Spearman´s correlation coefficients and linear regression analyses, using sex and age as covariates, were used to describe associations of blood SFAs with metabolic phenotype, functional capacity, cardiac function, and neurohumoral activation at baseline and after 12-month follow-up (12 mFU). Results: In line with prior data supporting a potential role of de novo lipogenesis-related LCSFAs in the development of HF, we showed that baseline blood levels of C14:0 and C16:0 were associated with cardiovascular risk factors and/or lower exercise capacity in patients with HFpEF at baseline/12 mFU. Contrarily, the three major circulating VLSFAs, lignoceric acid (C24:0), behenic acid (C22:0), and arachidic acid (C20:0), as well as the LCSFA C18:0, were broadly associated with a lower risk phenotype, particularly a lower risk lipid profile. No associations were found between cardiac function and blood SFAs. Conclusions: Blood SFAs were differentially linked to biomarkers and anthropometric markers indicative of a higher-/lower-risk cardiometabolic phenotype in HFpEF patients. Blood SFA warrant further investigation as prognostic markers in HFpEF. One Sentence Summary: In patients with HFpEF, individual circulating blood SFAs were differentially associated with cardiometabolic phenotype and aerobic capacity."],["dc.description.sponsorship","German Foundation of Heart Research"],["dc.description.sponsorship","Federal Ministry of Education and research"],["dc.identifier.doi","10.3390/biomedicines10092296"],["dc.identifier.pii","biomedicines10092296"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114500"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-600"],["dc.publisher","MDPI"],["dc.relation.eissn","2227-9059"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","214"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","223"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Holzendorf, Volker"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Schmidt, Albrecht G."],["dc.contributor.author","Kraigher-Krainer, Elisabeth"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Unkelbach, Ines"],["dc.contributor.author","Duengen, Hans-Dirk"],["dc.contributor.author","Tschoepe, Carsten"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Stough, Wendy Gattis"],["dc.contributor.author","Pieske, Burkert M."],["dc.date.accessioned","2017-09-07T11:44:38Z"],["dc.date.available","2017-09-07T11:44:38Z"],["dc.date.issued","2015"],["dc.description.abstract","AimsGalectin-3 is a marker of myocardial fibrosis and mediates aldosterone-induced cardiovascular inflammation and fibrosis. Characteristics of galectin-3 and its response to spironolactone have not been evaluated in heart failure with preserved ejection fraction (HFpEF). The aim of this study was to determine the association between galectin-3 levels and patient characteristics in HFpEF; to evaluate the interaction between spironolactone and galectin-3 levels; and to assess the association between galectin-3 and clinical outcomes. Methods and resultsAldo-DHF investigated spironolactone 25mg once daily vs. placebo for 12 months in patients with NYHA class II-III, LVEF 50%, gradeI diastolic dysfunction, and peakVO(2)25mL/kg/min. Galectin-3 levels were obtained at baseline, and at 6 and 12 months. The association between baseline galectin-3, change in galectin-3, and all-cause death or hospitalization was evaluated, and the interaction between galectin-3 and treatment was assessed. Median baseline galectin-3 was 12.1ng/mL. After multivariable adjustment, baseline galectin-3 inversely correlated with peak VO2 (P=0.021)(,) 6min walk distance (P=0.002), and Short Form 36 (SF-36) physical functioning (P=0.001), and directly correlated with NYHA class (P=0.007). Baseline NT-proBNP correlated with E/e' velocity ratio (P 0.001), left atrial volume index (P<0.001), and LV mass index (P=0.009). Increasing galectin-3 at 6 or 12 months was associated with all-cause death or hospitalization independent of treatment arm [hazard ratio (HR) 3.319, 95% confidence interval (CI) 1.214-9.07, P=0.019] and NT-proBNP (HR 3.127, 95% CI 1.144-8.549, P=0.026). Spironolactone did not influence galectin-3 levels. ConclusionGalectin-3 levels are modestly elevated in patients with stable HFpEF and relate to functional performance and quality of life. Increasing galectin-3 was associated with worse outcome, independent of treatment or NT-proBNP."],["dc.identifier.doi","10.1002/ejhf.203"],["dc.identifier.gro","3141963"],["dc.identifier.isi","000349675200016"],["dc.identifier.pmid","25418979"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11677"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/3024"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1879-0844"],["dc.relation.issn","1388-9842"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","591"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Bahls, Martin"],["dc.contributor.author","Friedrich, Nele"],["dc.contributor.author","Pietzner, Maik"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Budde, Kathrin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Nauck, Matthias"],["dc.contributor.author","Pressler, Axel"],["dc.contributor.author","Felix, Stephan B."],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Dörr, Marcus"],["dc.date.accessioned","2020-12-10T18:47:11Z"],["dc.date.available","2020-12-10T18:47:11Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.3390/jcm8050591"],["dc.identifier.eissn","2077-0383"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16443"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78674"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","408"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International Journal of Cardiology"],["dc.bibliographiccitation.lastpage","417"],["dc.bibliographiccitation.volume","169"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Stahrenberg, Raoul"],["dc.contributor.author","Behrens, Anneke"],["dc.contributor.author","Prettin, Christiane"],["dc.contributor.author","Kraigher-Krainer, Elisabeth"],["dc.contributor.author","Schmidt, Albrecht G."],["dc.contributor.author","Duengen, Hans-Dirk"],["dc.contributor.author","Kamke, Wolfram"],["dc.contributor.author","Tschoepe, Carsten"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Pieske, Burkert"],["dc.date.accessioned","2017-09-07T11:47:02Z"],["dc.date.available","2017-09-07T11:47:02Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: To investigate the interaction of clinical characteristics with disease characterising parameters in heart failure with preserved ejection fraction (HFpEF). Methods and results In the multicenter, randomized, placebo-controlled, double-blinded, Aldo-DHF trial investigating the effects of spironolactone on exercise capacity (peakVO2) and diastolic function (E/e') n=422 patients with HFpEF (age 67 +/- 8years, 52% females, LVEF 67 +/- 8%) were included. After multiple adjustment, higher age was significantly related to reduced peakVO2, and to increased E/e', NT-proBNP, LAVI as well as LVMI (all p < 0.05). Female gender (p < 0.001), CAD (p=0.002), BMI (p < 0.001), sleep apnoea (p=0.02), and chronotropic incompetence (CI, p=0.002) were related to lower peakVO2 values. Higher pulse pressure (p=0.04), lower heart rates (p=0.03), CI (p=0.03) and beta-blocker treatment (p=0.001) were associated with higher E/e'. BMI correlated inversely (p=0.03), whereas atrial fibrillation (p < 0.001), lower haemoglobin levels (p < 0.001), CI (p=0.02), and beta-blocker treatment (p < 0.001) were associated with higher NT-proBNP. After multiple adjustment for demographic and clinical variables peakVO2 was not significantly associated with E/e' (r=+0.01, p=0.87), logNT-proBNP (r=0.09, p=0.08), LAVI (r=+0.03, p=0.55), and LVMI (r=+0.05, p=0.37). The associations of E/e' with logNT-proBNP (r=0.21, p < 0.001), LAVI (r=+0.29, p < 0.001) and LVMI (r=0.09, p=0.06) were detectable also after multiple adjustment. Conclusions: Demographic and clinical characteristics differentially interact with exercise capacity, resting left ventricular filling index, neurohumoral activation, and left atrial and ventricular remodelling in HFpEF. Exercise intolerance in HFpEF is multi-factorial and therapeutic approaches addressing exercise capacity should therefore not only aim to improve single pathological mechanisms. Registration: ISRCTN94726526 (http://www.controlled-trials.com), Eudra-CT-number 2006-002605-31. (C) 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.ijcard.2013.10.018"],["dc.identifier.gro","3142247"],["dc.identifier.isi","000327141500013"],["dc.identifier.pmid","24182675"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11327"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/6165"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Elsevier Ireland Ltd"],["dc.relation.eissn","1874-1754"],["dc.relation.issn","0167-5273"],["dc.rights","CC BY-NC-SA 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-sa/3.0"],["dc.title","Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction - Results of the Aldo-DHF trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","56"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","65"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Trippel, Tobias Daniel"],["dc.contributor.author","Holzendorf, Volker"],["dc.contributor.author","Halle, Martin"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Nolte, Kathleen"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Schwarz, Silja"],["dc.contributor.author","Rutscher, Tinka"],["dc.contributor.author","Wiora, Julian"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Duengen, Hans-Dirk"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Edelmann, Frank"],["dc.date.accessioned","2018-04-23T11:48:18Z"],["dc.date.available","2018-04-23T11:48:18Z"],["dc.date.issued","2017"],["dc.description.abstract","Background Over 50% of patients with symptomatic heart failure (HF) experience HF with preserved ejection fraction (HFpEF). Exercise training (ET) is effective in improving cardiorespiratory fitness and dimensions of quality of life in patients with HFpEF. A systemic pro‐inflammatory state induced by comorbidities as the cause of myocardial structural and functional alterations has been proposed in HFpEF. ET modifies myocardial structure and has been related to inflammatory state. We investigated Ghrelin, related adipokines, markers of inflammation, and neuro‐hormonal activation in patients undergoing a structured ET vs. usual care are with HFpEF. Methods and results Ex‐DHF‐P was a prospective, controlled, randomized multi‐centre trial on structured and supervised ET in patients with HFpEF. We performed a post hoc analysis in 62 patients from Ex‐DHF‐P. Ghrelin, adiponectin, leptin, IL‐1ß, IL‐6, IL‐10, tumour necrosis factor‐alpha, MR‐proANP, MR‐proADM, CT‐proET1, and CT‐proAVP were assessed to seize the impact of ET on these markers in patients with HFpEF. Thirty‐six (58%) patients were female, mean age was 64 years, and median ghrelin was 928 pg/mL (interquartile range 755–1156). When stratified for high versus low ghrelin, groups significantly differed at baseline in presence obesity, waist circumference, and adiponectin levels (P < 0.05, respectively). Overall, ghrelin levels rose significantly to 1013 pg/mL (interquartile range 813–1182) (P < 0.001). Analysis of covariance modelling for change in ghrelin identified ET (P = 0.013) and higher baseline adiponectin levels (P = 0.035) as influencing factors. Conclusions Exercise training tended to increase ghrelin levels in Ex‐DHF‐P. This increase was especially pronounced in patients with higher baseline adiponectin levels. Future trials are needed to investigate the effect of ET on endogenous ghrelin levels in regard to interactions with cardiac structure and clinically meaningful surrogate parameters."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2016"],["dc.identifier.doi","10.1002/ehf2.12109"],["dc.identifier.gro","3142348"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14087"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/13484"],["dc.language.iso","en"],["dc.notes.intern","lifescience updates Crossref Import"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.relation.issn","2055-5822"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]